Innotherapy Stock Fundamentals
| 246960 Stock | KRW 8,370 340.00 3.90% |
InnoTherapy fundamentals help investors to digest information that contributes to InnoTherapy's financial success or failures. It also enables traders to predict the movement of InnoTherapy Stock. The fundamental analysis module provides a way to measure InnoTherapy's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to InnoTherapy stock.
InnoTherapy |
InnoTherapy Company Shares Outstanding Analysis
InnoTherapy's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current InnoTherapy Shares Outstanding | 5.04 M |
Most of InnoTherapy's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, InnoTherapy is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, InnoTherapy has 5.04 M of shares currently outstending. This is much higher than that of the sector and significantly higher than that of the Pharmaceuticals industry. The shares outstanding for all Republic of Korea stocks is notably lower than that of the firm.
InnoTherapy Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining InnoTherapy's current stock value. Our valuation model uses many indicators to compare InnoTherapy value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across InnoTherapy competition to find correlations between indicators driving InnoTherapy's intrinsic value. More Info.InnoTherapy is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value InnoTherapy by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for InnoTherapy's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.InnoTherapy Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses InnoTherapy's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of InnoTherapy could also be used in its relative valuation, which is a method of valuing InnoTherapy by comparing valuation metrics of similar companies.InnoTherapy is currently under evaluation in shares outstanding category among its peers.
InnoTherapy Fundamentals
| Return On Equity | -66.34 | |||
| Return On Asset | -0.13 | |||
| Operating Margin | (6.16) % | |||
| Current Valuation | 84.92 B | |||
| Shares Outstanding | 5.04 M | |||
| Shares Owned By Insiders | 28.30 % | |||
| Shares Owned By Institutions | 0.20 % | |||
| Price To Sales | 97.27 X | |||
| Revenue | 507.29 M | |||
| Gross Profit | 339.33 M | |||
| EBITDA | (3.23 B) | |||
| Net Income | (5.04 B) | |||
| Cash And Equivalents | 1.03 B | |||
| Cash Per Share | 375.11 X | |||
| Total Debt | 17.17 B | |||
| Debt To Equity | 0.56 % | |||
| Current Ratio | 6.75 X | |||
| Cash Flow From Operations | (3.98 B) | |||
| Number Of Employees | 26 | |||
| Beta | 1.49 | |||
| Market Capitalization | 44.19 B | |||
| Total Asset | 31.88 B | |||
| Z Score | 1.2 | |||
| Net Asset | 31.88 B |
About InnoTherapy Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze InnoTherapy's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InnoTherapy using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InnoTherapy based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.InnoTherapy, Inc., engages in the development and sale of medical sealant products in South Korea. The company was founded in 2010 and is headquartered in Seoul, South Korea. InnoTherapy is traded on Korean Securities Dealers Automated Quotations in South Korea.
Pair Trading with InnoTherapy
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if InnoTherapy position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in InnoTherapy will appreciate offsetting losses from the drop in the long position's value.Moving together with InnoTherapy Stock
| 0.74 | 102940 | Kolon Life Science | PairCorr |
| 0.63 | 074430 | Aminologics CoLtd | PairCorr |
| 0.81 | 047920 | HLB Pharmaceutical | PairCorr |
Moving against InnoTherapy Stock
The ability to find closely correlated positions to InnoTherapy could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace InnoTherapy when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back InnoTherapy - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling InnoTherapy to buy it.
The correlation of InnoTherapy is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as InnoTherapy moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if InnoTherapy moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for InnoTherapy can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in InnoTherapy Stock
InnoTherapy financial ratios help investors to determine whether InnoTherapy Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in InnoTherapy with respect to the benefits of owning InnoTherapy security.